Clinical Trial: A Phase 2 Clinical Trial Evaluating the Efficacy of a Single Administration of Pembrolizumab in the Neoadjuvant Setting.

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07448831) titled 'A Phase 2 Clinical Trial Evaluating the Efficacy of a Single Administration of Pembrolizumab in the Neoadjuvant Setting.' on Feb. 09.

Brief Summary: This study, called NeoSenti, is exploring whether giving one dose of the immunotherapy drug pembrolizumab before surgery can help the immune system fight melanoma more effectively. The study includes adults with high-risk melanoma who do not show any signs of the cancer having spread on scans. Participants receive a single infusion of pembrolizumab six weeks before their scheduled sentinel lymph node biopsy. The goal is to see if this early treatment can reduce or eliminate tiny cancer ...